New Milestone in Endometriosis Research: First Patient Treated with Vipoglanstat in Phase 2 Trial

Endometriosis is a chronic inflammatory disease that affects an estimated 190 million women worldwide. The disease can cause severe pain and is a common cause of infertility. Despite the high number of people affected, available treatment options have been limited to date.

With Vipoglanstat, Gesynta Pharma is developing a non-hormonal and non-opioid therapeutic approach that could open up new possibilities for patients. Many currently available therapies interfere with hormonal balance or are only suitable for long-term treatment to a limited extent.

The NOVA clinical trial is a randomized, double-blind, placebo-controlled Phase 2 study. Its goal is to investigate the efficacy and safety of Vipoglanstat.

In the study, two different doses of the active ingredient will be compared with a placebo. Additionally, the study aims to gain important insights into the optimal dosage for future studies.

Approximately 190 women between the ages of 18 and 45 will participate in the trial. The clinical trial sites are located in several European countries, including:

• United Kingdom

• Italy

• Poland

• Romania

• Bulgaria

• Czech Republic

• Hungary

The study represents an important step in the clinical development of Vipoglanstat.

With the launch of the Phase 2 study, Gesynta Pharma is moving closer to its goal of developing a new treatment option for endometriosis. Should the active ingredient prove to be effective and safe in the study, it could, in the long term, serve as an alternative to existing forms of therapy.

For many patients worldwide, this could represent a significant advance in the treatment of this often highly debilitating condition.

---

For more information, click here.